Amgen Execs to Present at Bank of America Healthcare Conference
Event summary
- Amgen to present at Bank of America Merrill Lynch Global Healthcare Conference on May 13, 2026.
- Peter Griffith (CFO) and Jay Bradner (EVP of R&D) to lead the presentation.
- Webcast available live and archived for 90 days post-event.
- Amgen focuses on innovative medicines for cancer, inflammatory conditions, rare diseases, heart disease, and obesity.
The big picture
Amgen's participation in the Bank of America Merrill Lynch Global Healthcare Conference underscores its strategic focus on innovation and financial transparency. As a key player in the biotech sector, Amgen's updates on its pipeline and financial health will be closely watched by investors and competitors alike. The company's inclusion in the Dow Jones Industrial Average and Nasdaq-100 Index highlights its significant market presence and the importance of its strategic moves.
What we're watching
- Pipeline Progress
- How Amgen's R&D updates will impact investor confidence in its pipeline.
- Financial Strategy
- Whether Amgen's financial guidance aligns with market expectations.
- Competitive Positioning
- The pace at which Amgen can differentiate itself in the crowded biotech space.
Related topics